Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (DE:2CL)
MUNICH:2CL
BridgeBio Pharma (2CL) Stock Price & Analysis
3 Followers
2CL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€11.70 - €39.72
Previous Close€23.53
Volume0.00
Average Volume (3M)181.00
Market Cap
€4.72B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta1.16
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume181
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€46.66Price Target Upside98.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
BridgeBio Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAcoramidis achieved 42% relative risk reduction at 30 months on all-cause mortality and CV hospitalizations.
Drug Development ProgressBBIO has multiple late stage assets that are highly clinically de-risked.
Financial AnalysisAnalysts maintain a Buy rating and a Price Target of $50, indicating a belief in the stock's potential growth.
Bears Say
Clinical Trial ConcernsHELIOS-B trial primary endpoint changed to include the monotherapy population.
Financial PerformanceBridgeBio Pharma shares have underperformed with a notable decline, reflecting investor concerns.
Market CompetitionPotential market entry of Tafamidis generics and ongoing litigation over generic Tafamidis could impact Acoramidis uptake.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.73% Other Institutional Investors
99.27% Public Companies and
Individual Investors
2CL FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was €11.70 and its highest was €39.72 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
Currently, no data Available
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Aug 01, 2024 which is in 89 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on May 02, 2024. The company reported -€0.187 earnings per share for the quarter, beating the consensus estimate of -€0.688 by €0.501.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Pharma Inc have?
Currently, no data Available
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -€0.187 in its last earnings report, beating expectations of -€0.688. Following the earnings report the stock price went up 5.567%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 1B.
---
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€46.66 (98.30% Upside)
€46.66 (98.30% Upside)
Blogger Sentiment
Bullish
DE:2CL Sentiment 85%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $44.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
98.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.75%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
2CL Stock 12 Months Forecast
Average Price Target
€46.66
▲(98.30% Upside)
Technical Analysis
BridgeBio Pharma
―
BioLife Solutions
―
Crinetics Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering 2CL
1 Year
1 Year Success Rate
23/40 ratings generated profit
1 Year Average Return
+41.78%
reiterated a buy rating 4 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 57.50% of your transactions generating a profit, with an average return of +41.78% per trade.
---